Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review.

IF 5.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Current Diabetes Reports Pub Date : 2024-05-01 Epub Date: 2024-03-01 DOI:10.1007/s11892-024-01537-3

Reza Pishdad, Paul G Auwaerter, Rita R Kalyani

{"title":"Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review.","authors":"Reza Pishdad, Paul G Auwaerter, Rita R Kalyani","doi":"10.1007/s11892-024-01537-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: The aim of this review is to focus on epidemiology, pathogenesis, risk factors, management, and complications of UTI in people with diabetes as well as reviewing the association of SGLT-2 inhibitors with genitourinary infections.Recent findings: Individuals diagnosed with T2DM are more prone to experiencing UTIs and recurrent UTIs compared to individuals without T2DM. T2DM is associated with an increased risk of any genitourinary infections (GUI), urinary tract infections (UTIs), and genital infections (GIs) across all age categories. SGLT2 inhibitors are a relatively new class of anti-hyperglycemic agents, and studies suggest that they are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications with a patient-centric approach are the most recognized methods for preventing critical long-term complications including genitourinary manifestations of diabetes. The available data regarding the association of SGLT-2 inhibitors with genitourinary infections is more comprehensive compared to that with UTIs. Further research is needed to better understand the mechanisms underlining the association between SGLT-2 inhibitors and genital infections and UTIs.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"108-117"},"PeriodicalIF":5.2000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Diabetes Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11892-024-01537-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The aim of this review is to focus on epidemiology, pathogenesis, risk factors, management, and complications of UTI in people with diabetes as well as reviewing the association of SGLT-2 inhibitors with genitourinary infections.

Recent findings: Individuals diagnosed with T2DM are more prone to experiencing UTIs and recurrent UTIs compared to individuals without T2DM. T2DM is associated with an increased risk of any genitourinary infections (GUI), urinary tract infections (UTIs), and genital infections (GIs) across all age categories. SGLT2 inhibitors are a relatively new class of anti-hyperglycemic agents, and studies suggest that they are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications with a patient-centric approach are the most recognized methods for preventing critical long-term complications including genitourinary manifestations of diabetes. The available data regarding the association of SGLT-2 inhibitors with genitourinary infections is more comprehensive compared to that with UTIs. Further research is needed to better understand the mechanisms underlining the association between SGLT-2 inhibitors and genital infections and UTIs.

Abstract Image

查看原文本刊更多论文

糖尿病、SGLT-2 抑制剂与尿路感染：综述。

综述目的：本综述旨在关注糖尿病患者 UTI 的流行病学、发病机制、风险因素、管理和并发症，以及 SGLT-2 抑制剂与泌尿生殖系统感染的关系：最新研究结果：与非 T2DM 患者相比，被诊断患有 T2DM 的患者更容易发生 UTI 和复发性 UTI。在所有年龄段中，T2DM 与泌尿生殖系统感染 (GUI)、尿路感染 (UTI) 和生殖器感染 (GI) 的风险增加有关。SGLT2 抑制剂是一类相对较新的降糖药物，研究表明它们与泌尿生殖系统感染风险增加有关。以患者为中心的糖尿病管理和生活方式调整是预防严重长期并发症（包括糖尿病的泌尿生殖系统表现）的公认方法。与UTIs相比，SGLT-2抑制剂与泌尿生殖系统感染相关的现有数据更为全面。要更好地了解 SGLT-2 抑制剂与生殖器感染和尿毒症之间的关联机制，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Diabetes Reports 医学 -

CiteScore

9.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The goal of this journal is to publish cutting-edge reviews on subjects pertinent to all aspects of diabetes epidemiology, pathophysiology, and management. We aim to provide incisive, insightful, and balanced contributions from leading experts in each relevant domain that will be of immediate interest to a wide readership of clinicians, basic scientists, and translational investigators. We accomplish this aim by appointing major authorities to serve as Section Editors in key subject areas across the discipline. Section Editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year on their topics, in a crisp and readable format. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.